| 4 | Fairmount Funds Management LLC | 2.5M | $247.3M | 0.0% | 6.077% | 16.35% |
| 5 | STATE STREET CORP | 2.4M | $229.8M | +68.5% | 5.647% | 0.00% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $210.5M | +6.3% | 5.173% | 0.00% |
| 7 | Avidity Partners Management LP | 2.1M | $205.1M | 0.0% | 5.040% | 32.85% |
| 8 | Octagon Capital Advisors LP | 1.8M | $179.5M | -5.4% | 4.411% | 16.14% |
| 9 | TCG Crossover Management, LLC | 1.7M | $163.4M | 0.0% | 4.016% | 3.93% |
| 10 | FRED ALGER MANAGEMENT, LLC | 1.3M | $127.0M | +12.1% | 3.120% | 0.42% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $122.7M | +37.4% | 3.014% | 0.01% |
| 12 | Venrock Adviser, LLC | 1.2M | $115.0M | 0.0% | 2.826% | 3.49% |
| 13 | UBS Group AG | 1.1M | $111.2M | +46.0% | 2.731% | 0.01% |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.1M | $109.7M | +10.3% | 2.695% | 1.14% |
| 15 | CITADEL ADVISORS LLC | 1.0M | $100.0M | -37.8% | 2.457% | 0.01% |
| 16 | JENNISON ASSOCIATES LLC | 1.0M | $99.6M | +110.6% | 2.447% | 0.06% |
| 17 | Polar Capital Holdings Plc | 1.0M | $99.3M | -5.3% | 2.440% | 0.23% |
| 18 | FRANKLIN TEMPLETON INC | 969K | $94.5M | +0.1% | 2.321% | 0.02% |
| 19 | BAKER BROS. ADVISORS LP | 852K | $83.1M | 0.0% | 2.041% | 0.42% |
| 20 | Logos Global Management LP | 800K | $78.0M | +100.0% | 1.916% | 3.36% |
| 21 | Cormorant Asset Management, LP | 750K | $73.1M | -21.1% | 1.796% | 3.75% |
| 22 | ALLIANCEBERNSTEIN L.P. | 834K | $70.0M | -9.9% | 1.998% | 0.02% |
| 23 | BRAIDWELL LP | 595K | $58.0M | -33.9% | 1.424% | 2.14% |
| 24 | VANGUARD PORTFOLIO MANAGEMENT LLC | 570K | $55.6M | +63.2% | 1.365% | 0.00% |
| 25 | AMERIPRISE FINANCIAL INC | 532K | $51.9M | +24.0% | 1.274% | 0.01% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DNTH — a direct measure of their conviction.
| 156.36% |
| +9.95 pp |
| $673M |
| 11% |
| Q4 2024 | 96 | +5.5% | 146.41% | +6.49 pp | $755M | 12% |
| Q3 2024 | 91 | — | 139.92% | — | $855M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
DNTH institutional ownership rose by 7.92 percentage points quarter-over-quarter, with a net change of +28 holders.
The top 10 institutions account for 49.8% of all reported 13F value in DNTH, and the top 25 account for 72.7%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.